Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Recursion Pharmaceuticals uses high-dimensional data and modern approaches to generate predictive results for drug discovery and development. The company has strengthened its tech stack through ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...